Biotech vet Troy Wil­son shines a spot­light on his oligonu­cleotide start­up as Eli Lil­ly signs up for a pre­mier Big Phar­ma part­ner­ship

Troy Wil­son is best known now for his role lead­ing Ku­ra On­col­o­gy, where the team has been de­vel­op­ing tar­get­ed can­cer drugs. Not so well known is Avid­i­ty Bio­sciences, which he and Kent Hawry­luk found­ed in La Jol­la about 6 years ago, us­ing an an­ti­body con­ju­gat­ed with oligonu­cleotides and siR­NA pay­loads to hit spe­cif­ic tar­gets of their own. 

But to­day they’d like to shed some of that low pro­file with a pre­mier dis­cov­ery part­ner­ship with Eli Lil­ly that will bring a much brighter spot­light to the work they’re do­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.